NCT04510675已完成不适用
A 6-Week, Randomized, Evaluator-Blinded, In Vivo Within Subject Repeat Test to Evaluate the Irritation and Sensitization Potential of Omeza Collagen Matrix in Healthy Volunteers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Omeza, LLC
- 入组人数
- 58
- 试验地点
- 2
- 主要终点
- Evidence of Erythema During the Challenge Phase for Omeza Collagen Matrix
研究概览
简要总结
The primary objective of this study was to assess the sensitization potential of Omeza Collagen Matrix compared to that of a negative control based on a Modified Human Repeat Insult Patch Test.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
盲法说明
The trained skin evaluator and Investigator was blinded to the identity of the test materials. Test/control sites were randomized within participants.
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Good general health, as assessed by medical history and brief dermal skin examination of the application site (back);
- •Was fully informed of the risks of entering the study and was willing to provide written consent to enter the study;
- •Was willing to follow study rules, which included: no sun exposure (for example; no swimming, sunbathing, or tanning beds), avoided activities that would cause excessive sweating, abstained from use of lotions, creams, or oils on the back area;
- •Was willing to not change current brand of personal care products such as soaps, body washes, laundry detergents, body sprays, body spritzes, etc. while participating on the study;
- •Was willing and able to practice an acceptable measure of contraception (i.e. birth control medication for at least 3 months prior, condom with spermicide or birth control injections,) during the study, if female of childbearing potential. To be considered female of non-childbearing potential, subject must have had a hysterectomy, tubal ligation, or had been post-menopausal for at least 1 year.
排除标准
- •Clinically significant skin disease which contraindicated participation, including psoriasis, eczema, atopic dermatitis, and active cancer;
- •Asthma that required medication;
- •Insulin-dependent diabetes;
- •Known immunological disorders such as HIV positive, AIDS and systemic lupus
- •erythematosus;
- •Treatment for any type of cancer within the last six months;
- •Routine use (as defined by using more than 3 days in a week) of any anti-inflammatory drug (e.g., aspirin, ibuprofen, corticosteroids; 81 mg aspirin is acceptable), immunosuppressive drugs, antihistamine medication (steroid nose drops and/or eye drops are acceptable) or over-the-counter pain medication that was ingested in quantities exceeding label instructions;
- •Use of topical drugs at patch site;
- •Pregnancy, lactation, or planning a pregnancy (confirmed by a urine pregnancy test administered to females of childbearing potential);
- •Medical condition which, in the Investigator's judgement, made the subject
- •ineligible or placed the subject at undue risk;
- •Participation in any patch test for irritation or sensitization within the last four weeks;
- •Dermatological aberrations in or around test sites which included sunburn, extremely deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or any other disfiguration of the test site;
- •Confirmed allergy to adhesives, bandages, or ingredients in OmezaTM Collagen Matrix;
- •History of anaphylaxis to matrix ingredients (e.g. fish, palm oil, hemp oil, beeswax).
结局指标
主要结局
Evidence of Erythema During the Challenge Phase for Omeza Collagen Matrix
时间窗: 24, 48, 72, and 96 Hours
Erythema is evaluated during the challenge phase based on a numeric scale from 0 - 3 (0: No visible reaction, +: Slight/patchy, 1: Mild, 2: Moderate, 3: Strong). A score of 1, 2, or 3 indicates dermal sensitization.
次要结局
- Adverse Events Deemed Related to the Test Product or the Study(6 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
3 期
Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People's HospitalGlaucomasPterygiumNCT00478790Pro Top & Mediking Company Limited60
已完成
不适用
Effects of Collagen Peptide Supplementation on Muscle and Tendon Damage and FunctionExerciseHealthy Male SubjectsNCT05425407KU Leuven22
已完成
3 期
Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan HospitalGlaucomasPterygiumNCT00320957Pro Top & Mediking Company Limited61
已完成
3 期
Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing HospitalGlaucomaPterygiumNCT00320762Pro Top & Mediking Company Limited60
招募中
不适用
Collagen for Treatment of Musculoskeletal InjuriesAnterior Cruciate Ligament InjuriesHallux RigidusNCT06331741I.M. Sechenov First Moscow State Medical University15